Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Validation of the first commercial ELISA for type 2N von Willebrand's disease diagnosis.

Haemophilia : the official journal of the World Federation of Hemophilia - 1 Nov 2011

Veyradier A, Caron C, Ternisien C, Wolf M, Trossaert M, Fressinaud E, Goudemand J

Abstract excerpt

Type 2N von Willebrand's disease (VWD) is characterized by a factor VIII (FVIII) deficiency and a low FVIII/VWF ratio related to a markedly decreased affinity of von Willebrand factor (VWF) to FVIII. Type 2N VWD is diagnosed using assays allowing the measurement of plasma VWF capacity to bind FVIII (VWF:FVIIIB). These assays, crucial in order to distinguish type 2N VWD patients from mild haemophiliacs A and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Enzyme-Linked Immunosorbent Assay
Share to Factor VIII

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hemophilia A

Share to Reagent Kits, Diagnostic

Share to Reference Values

Share to von Willebrand Disease, Type 2

Share to von Willebrand Diseases

Share to von Willebrand Factor

Source

Identifiers

PMID: 21371195
DOI: 10.1111/j.1365-2516.2011.02499.x

Genes

VWF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Validation of the first commercial ELISA for type 2N von Willebrand's disease diagnosis.PMID 21371195Read ↗

Type 2N von Willebrand disease: Characterization and diagnostic difficulties.Semantic proximity Read ↗

Clinical diagnosis of von Willebrand disease.Semantic proximity Read ↗

Measurement of von Willebrand factor-FVIII binding activity in patients with suspected von Willebrand disease type 2N: application of an ELISA-based assay in a reference laboratory.Semantic proximity Read ↗

Comparison of a new chemiluminescent immunoassay for von Willebrand factor activity with the ristocetin cofactor-induced platelet agglutination method.Semantic proximity Read ↗

Large experience with a factor VIII binding assay of plasma von Willebrand factor using commercial reagents.Semantic proximity Read ↗

Rapid discrimination of the phenotypic variants of von Willebrand disease.Semantic proximity Read ↗

Evaluation of an automated screening assay for von Willebrand disease type 2N.Semantic proximity Read ↗

Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.Semantic proximity Read ↗

Evaluation of an heterogeneous group of patients with von Willebrand disease using an assay alternative to ristocetin induced platelet agglutination.Semantic proximity Read ↗

[Type 2N von Willebrand disease (Normandy)].Semantic proximity Read ↗

Performance and clinical utility of a commercial von Willebrand factor collagen binding assay for laboratory diagnosis of von Willebrand disease.Semantic proximity Read ↗

Type 2M von Willebrand disease - more often misidentified than correctly identified.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.